JP6321298B2 - α−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛の乾癬を治療するための使用 - Google Patents
α−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛の乾癬を治療するための使用 Download PDFInfo
- Publication number
- JP6321298B2 JP6321298B2 JP2017530371A JP2017530371A JP6321298B2 JP 6321298 B2 JP6321298 B2 JP 6321298B2 JP 2017530371 A JP2017530371 A JP 2017530371A JP 2017530371 A JP2017530371 A JP 2017530371A JP 6321298 B2 JP6321298 B2 JP 6321298B2
- Authority
- JP
- Japan
- Prior art keywords
- psoriasis
- photosensitizer
- quinolinyloxy
- group
- treating psoriasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000004681 Psoriasis Diseases 0.000 title claims description 42
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 title claims description 24
- -1 8-quinolinyloxy Chemical group 0.000 title claims description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims description 13
- 229910052725 zinc Inorganic materials 0.000 title claims description 13
- 239000011701 zinc Substances 0.000 title claims description 13
- 238000002428 photodynamic therapy Methods 0.000 claims description 28
- 239000003504 photosensitizing agent Substances 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004065 semiconductor Substances 0.000 claims description 3
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 239000003814 drug Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000005286 illumination Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 241000700199 Cavia porcellus Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 229960003712 propranolol Drugs 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000003780 keratinization Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 6
- 229960000452 diethylstilbestrol Drugs 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 230000000394 mitotic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940126702 topical medication Drugs 0.000 description 3
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 1
- 229940027041 8-mop Drugs 0.000 description 1
- 101100002669 Arabidopsis thaliana ADT1 gene Proteins 0.000 description 1
- 101100002673 Arabidopsis thaliana ADT3 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical class [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100463170 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pdt1 gene Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
Description
Claims (8)
- 下記の構造式を有するα−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛を有効成分とすることを特徴とする乾癬治療用の光増感剤。
- 前述乾癬が尋常性乾癬、膿疱性乾癬、乾癬性紅皮症、又は関節症性乾癬の種類を含み、中医学分類として血熱型、血燥型、又はお血型の種類を含む、請求項1に記載の乾癬治療用の光増感剤。
- 光線力学治療法のためのものである、請求項1又は2記載の乾癬治療用の光増感剤。
- 前記光線力学治療法の光源が半導体レーザーである、請求項1〜3のいずれか1つに記載の乾癬治療用の光増感剤。
- 請求項1〜4のいずれかに記載の乾癬治療用の光増感剤と、溶液、クリーム、ナノミセル、微粒子、及び傷当てからなる群から選ばれた1種又は2種以上とを組み合わせてなる乾癬治療用組成物。
- 全身投薬或いは局所投薬のためのものである、請求項5記載の乾癬治療用組成物。
- 乾癬治療用の光増感剤の製造のための下記の構造式を有するα−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛の使用。
- 乾癬治療用組成物の製造のための下記の構造式を有するα−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410438091.7A CN105363031B (zh) | 2014-09-01 | 2014-09-01 | α-(8-喹啉氧基)单取代酞菁锌治疗银屑病的用途 |
CN201410438091.7 | 2014-09-01 | ||
PCT/CN2014/000819 WO2016033705A1 (zh) | 2014-09-01 | 2014-09-02 | α-(8-喹啉氧基)单取代酞菁锌治疗银屑病的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017535594A JP2017535594A (ja) | 2017-11-30 |
JP6321298B2 true JP6321298B2 (ja) | 2018-05-09 |
Family
ID=55365983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017530371A Active JP6321298B2 (ja) | 2014-09-01 | 2014-09-02 | α−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛の乾癬を治療するための使用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10058611B2 (ja) |
JP (1) | JP6321298B2 (ja) |
CN (1) | CN105363031B (ja) |
WO (1) | WO2016033705A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082034A (zh) * | 2021-04-16 | 2021-07-09 | 南方医科大学 | 凡德他尼在制备寻常型银屑病治疗药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753381A (ja) * | 1993-07-09 | 1995-02-28 | Ciba Geigy Ag | 局所投与可能な亜鉛フタロシアニン組成物 |
GB9500116D0 (en) * | 1995-01-05 | 1995-03-01 | Ciba Geigy Ag | Pharmaceutical compositions |
IT1294325B1 (it) * | 1997-08-14 | 1999-03-24 | Molteni L E C Dei Fratelli Ali | Zinco-ftalocianine e relativi coniugati, preparazione e uso nella terapia fotodinamica e come diagnostici |
CN101260110B (zh) * | 2008-04-11 | 2010-06-02 | 福州大学 | α-(8-喹啉氧基)单取代酞菁锌及其制备方法 |
CN101485660B (zh) * | 2009-03-09 | 2012-02-01 | 王英明 | α-(8-喹啉氧基)单取代酞菁锌抗肿瘤的用途 |
CN102284059A (zh) * | 2011-08-23 | 2011-12-21 | 福州大学 | 一种光敏剂及其制备方法和应用 |
-
2014
- 2014-09-01 CN CN201410438091.7A patent/CN105363031B/zh active Active
- 2014-09-02 US US15/508,023 patent/US10058611B2/en active Active
- 2014-09-02 JP JP2017530371A patent/JP6321298B2/ja active Active
- 2014-09-02 WO PCT/CN2014/000819 patent/WO2016033705A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016033705A1 (zh) | 2016-03-10 |
US10058611B2 (en) | 2018-08-28 |
JP2017535594A (ja) | 2017-11-30 |
CN105363031A (zh) | 2016-03-02 |
US20170296662A1 (en) | 2017-10-19 |
CN105363031B (zh) | 2019-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Diamond et al. | Photodynamic therapy of malignant tumours | |
DE60211918T2 (de) | Sulfonierte chlorine als photosensitizer | |
CN108452303A (zh) | 一种载双药纳米制剂及其制备方法 | |
CN103040864B (zh) | 磷酸硒盐复合物的医药用途 | |
EP2026657A1 (en) | Anti-cancer composition and method for using the same | |
JP6321298B2 (ja) | α−(8−キノリニルオキシ)モノ置換フタロシアニン亜鉛の乾癬を治療するための使用 | |
CN102641278A (zh) | 银杏酚酸在治疗关节炎中的用途 | |
CN101467996B (zh) | 次卟啉衍生物的用途 | |
CN101744795B (zh) | 一种治疗鲜红斑痣的药物组合物及其制备方法 | |
CN110354133A (zh) | 四氢生物蝶呤的应用及药物 | |
JP7436471B2 (ja) | 基底細胞癌および神経膠芽腫を治療する方法 | |
US10369170B1 (en) | Methods of treating basal cell carcinoma and glioblastoma | |
CN110051734B (zh) | 一种抗结肠炎相关性结肠癌的药物组合物及其应用 | |
CN101485660B (zh) | α-(8-喹啉氧基)单取代酞菁锌抗肿瘤的用途 | |
WO2020199973A1 (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
CN110151990A (zh) | 一种酞菁-温敏凝胶制剂及其制备方法 | |
KR101089750B1 (ko) | 5―히드록시인돌초산을 포함하는 광감작용 조성물 및 이를 포함하는 암의 광역학 치료용 조성물 | |
WO2022100750A1 (zh) | 可用于光动力治疗或诊断的制剂 | |
US20080038376A1 (en) | Anti-cancer composition and method for using the same | |
JP7101105B2 (ja) | 超音波増感剤 | |
CN108606985A (zh) | 一种用于治疗角化型手足癣的复方水杨酸洗剂及其制备方法 | |
Rahmadianti et al. | Antioxidant Gel from Brown Algae (Ascophyllum nodosum) and Binahong Leaves for Diabetic Wound Healing | |
WO2016028633A2 (en) | Transition metal porphyrin complexes and methods of threatment using same | |
TWI406658B (zh) | 使用異硫氰酸酯類來治療癌症之方法及用途 | |
CN103816116B (zh) | 一种治疗皮肤癌的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180320 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180404 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6321298 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |